Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olpadronic acid
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Olpadronic acid is a nitrogen-containing bisphosphonate, a derivative of pamidronate, that functions as an inhibitor of bone resorption. It has been investigated for its use in conditions characterized by excessive bone breakdown, such as hypercalcemia of malignancy and Paget's disease of bone. Its mechanism involves inhibiting the activity of osteoclasts, the cells responsible for bone resorption.
- Other names
- dimethyl-APDdimethylaminohydroxypropylidene bisphosphonate[3-dimethyl-amino-1-hydroxypropylidene]-1,1-bisphosphonate
Beyond the preview
Go deeper on olpadronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olpadronic acid.